A Long Term Evaluation Of MariTide In Adults Who Are Obese Or Overweight (MARITIME-1-EXTENSION)

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight

• IRAS ID

  1014015

• Contact name

  Matthew Rodaway

• Contact email

  gbinfoline@amgen.com

• Sponsor organisation

  Amgen Inc.

• Eudract number

  2026-525408-82

• Clinicaltrials.gov Identifier

  NCT07684235

• Research summary

  Obesity is a long-term health condition that has an impact on quality of life and can increase the risk of other serious health problems. Many people lose weight with obesity medicines but often gain weight back after stopping treatment. This study is testing a medicine called maridebart cafraglutide to see how safe and effective it is for helping people with overweight or obesity keep weight off for longer time. This is a roll-over study and will only include participants who previously took part in the parent study (IRAS 1011192) of this medicine.
  Researchers want to learn if taking maridebart cafraglutide for longer, or taking it less often, can help people maintain their weight loss. The study aims to understand how well the medicine works over a longer time, how safe and tolerable continued treatment is, and what impact taking it less often could have on long-term obesity treatment.
  Only people who completed the parent study and agree to continue can join this study. Participants will be placed into groups based on the treatment they received in the earlier study. In this study, participants will be randomly assigned to receive different doses of maridebart cafraglutide, receive the medicine at different times, or receive a placebo (a substance with no active medicine that looks like the study drug). Neither the participants nor the study team will know which treatment is being given. This study does not replace regular medical care. Participants will continue to attend study visits, which may include health checks, body weight measurements, blood tests, and questions about how they are feeling. The results of this study will help researchers better understand the long-term benefits and risks of maridebart cafraglutide and may support the future development of treatments for people living with obesity.

• REC name

  Wales REC 3

• REC reference

  26/WA/0175

• Date of REC Opinion

  22 Jul 2026

• REC opinion

  Further Information Favourable Opinion